105 related articles for article (PubMed ID: 1686602)
41. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia.
Campiotti L; Grandi AM; Biotti MG; Ultori C; Solbiati F; Codari R; Venco A
Am J Hematol; 2007 Mar; 82(3):231-3. PubMed ID: 17022045
[TBL] [Abstract][Full Text] [Related]
42. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
Kuyama J; Take H
Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
[TBL] [Abstract][Full Text] [Related]
43. Leukemic synovitis as a presentation of myelomonocytic blast crisis of chronic myeloid leukemia.
Al-Rayes HM; Al-Shaikh AA; Halim MA; Al-Qurashi FS; Al-Jurf MM
Saudi Med J; 2001 Sep; 22(9):808-11. PubMed ID: 11590459
[TBL] [Abstract][Full Text] [Related]
44. [Chronic myelocytic leukemia in children].
Poliakov VE
Feldsher Akush; 1991 Nov; 56(11):23-9. PubMed ID: 1807975
[No Abstract] [Full Text] [Related]
45. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Dutcher JP; Eudey L; Wiernik PH; Paietta E; Bennett JM; Arlin Z; Kellermeyer R; Rowe J; O'Connell M; Oken M
Leukemia; 1992 Aug; 6(8):770-5. PubMed ID: 1379312
[TBL] [Abstract][Full Text] [Related]
46. Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
Fang B; Song Y; Han Z; Wei X; Lin Q; Zhu X; Yang R; Sun J; Tian G; Liu X; Cao G; Shi Y; Nie N; Li D; Zhao RC
Leuk Res; 2007 Oct; 31(10):1441-4. PubMed ID: 17383001
[TBL] [Abstract][Full Text] [Related]
47. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
[TBL] [Abstract][Full Text] [Related]
48. IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study.
Meloni G; Foà R; Tosti S; Vignetti M; Gavosto F; Mandelli F
Haematologica; 1990; 75(6):502-5. PubMed ID: 2098290
[TBL] [Abstract][Full Text] [Related]
49. [Graft vs. tumor effect in chronic granulocytic leukemia].
Ruiz-Argüelles GJ
Rev Invest Clin; 2002; 54(2):154-60. PubMed ID: 12053814
[No Abstract] [Full Text] [Related]
50. Optimizing treatment for chronic myeloid leukemia.
Goldman JM
N Engl J Med; 1997 Jul; 337(4):270-1. PubMed ID: 9227935
[No Abstract] [Full Text] [Related]
51. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
[TBL] [Abstract][Full Text] [Related]
52. [Rapamycin for myeloid blast crisis in refractory chronic myeloid leukemia with imatinib-resistance].
Xie J; Zhang X; Fang BZ
Zhonghua Xue Ye Xue Za Zhi; 2011 Aug; 32(8):553-4. PubMed ID: 22338181
[No Abstract] [Full Text] [Related]
53. A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.
Guilhot F; Lamagnère JP; Harousseau JL; Tilly H; Casassus P; Ifrah N; Rochant H; Bauters F; Dine G; Tanzer J
Eur J Cancer; 1991; 27 Suppl 4():S26. PubMed ID: 1799470
[No Abstract] [Full Text] [Related]
54. Evolving approaches with interferon alfa in chronic myelogenous leukemia.
Morra E; Alimena G; Lazzarino M; Liberati AM; Montefusco E; Bernasconi P; Mancini M; Donti E; Merante S; Caricchi P
Semin Hematol; 1993 Jul; 30(3 Suppl 3):26-7. PubMed ID: 8235701
[No Abstract] [Full Text] [Related]
55. Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML.
Guerrasio A; Martinelli G; Ambrosetti A; Falda M; Paolino F; Rege-Cambrin G; Rosso C; Pignatti PF; Gasparini P; Perona G
Haematologica; 1991; 76(2):126-30. PubMed ID: 1937170
[TBL] [Abstract][Full Text] [Related]
56. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
57. [The megakaryoblastic variant of the blast crisis in chronic myeloleukemia].
Volkova MA; Frenkel' MA; Lepkov SV; Tupitsyn NN
Ter Arkh; 1990; 62(7):127-9. PubMed ID: 2251650
[No Abstract] [Full Text] [Related]
58. Chronic myeloid leukemia with osteolytic bone involvement.
Prabhash K; Loknath D; Babu KG; Hasib AG; Biswas S; Bapsy PP
J Assoc Physicians India; 2003 Jul; 51():740-1. PubMed ID: 14621059
[No Abstract] [Full Text] [Related]
59. Chronic Myelogenous Leukemia Relapse Presenting With Central Nervous System Blast Crisis and Bilateral Optic Nerve Infiltration.
Mbekeani JN; Abdel Fattah M; Al Nounou RM; Chebbo W; Dogar MA
J Neuroophthalmol; 2016 Mar; 36(1):73-7. PubMed ID: 26628337
[TBL] [Abstract][Full Text] [Related]
60. [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis].
Kitajima K; Adachi T; Takahashi I; Nakada H; Osada K; Fukuda S; Ohmoto E; Aoyama S; Yorimitsu S; Sanada H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3573-9. PubMed ID: 2817908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
